HEDIMED

Human exposomic determinants of immune mediated diseases

The HEDIMED project comprises 22 partners from 12 different countries, and aims to identify the exposomic determinants that are driving the rapid increase of immune-mediated diseases (IMDs) such as type 1 diabetes, celiac disease, allergies and asthma.

The project will use data and samples from large clinical cohorts and trials from countries with both high and low IMD incidence. Exposomic disease determinants and the underlying biological pathways will be identified using advanced omics, multiplex and data-mining technologies.

Participants
  • Tampere University, Finland (Project Coordination)
  • Baylor College of Medicine, USA
  • Charles University, Czech Republic
  • Czech University of Life Sciences Prague, Czech Republic
  • Copenhagen Prospective Studies on Asthma in Childhood, Denmark
  • Empirica MBH, Germany
  • Finnish National Institute for Health and Welfare (THL), Finland
  • Gnomon Informatics SA, EL
  • Graz University of Technology, Austria
  • Natural Resources Institute, Finland
  • Norwegian Institute of Public Health, Norway
  • Pirkanmaa Hospital District, Finland
  • Satellio Oy, Finland
  • Swiss Center for Electronics and Microtechnology (CSEM SA)
  • Tartu University Clinic, Estonia
  • University of Helsinki, Finland
  • Lund University, Sweden
  • University of Oulu, Finland
  • University of Siena, Italy
  • University of Tartu, Estonia
  • University of Turku, Finland
  • VTT Technical Research Centre, Finland
Coordinator
Prof Heikki Hyöty
Tampere University Foundation, Finland
Scientific management team
  • Jutta Laiho
  • Leena Puustinen
  • Olli Laitinen
  • Johannes Malkamäki
Public deliverables

Title Description Ref Participant Format Due
Final management structure Management team structure for administration and reporting D1.1 TAU Report Feb 2020
State-of-art report Summary of current scientific research in the field covered by HEDIMED D1.2 TAU Report Feb 2020
Kick-off report Report from the kick-off meeting D1.3 TAU Report Feb 2020
HEDIMED project web site  Construction of project web site D10.1 VTT Website Feb 2020
Publication guidelines Scientific publication guidelines for scientific publications emerging from the HEDIMED project D11.1 TAU Report Mar 2020
Joint Network Advisory Board Report – EPHOR/REMEDIA/HEDIMED Members, mandate, rules and work plan for NAB D12.1 TAU Report Mar 2020
Ethical approval report Assurance that EU regulations (e.g. GDPR) will be followed in the analyses of samples and data D3.1 UOULU Report Mar 2020
Procedures securing protection of personal data Protection of personal identity of study subjects using procedures legally accepted by member states. Anonymized database to allow flexible analyses of the data by consortium members D3.2 UOULU Report Apr  2020
Definitions and criteria for study endpoints Definitions and criteria for study end points in all cohorts D2.1 NIPH Report May 2020
Data Management Plan Data Management Plan as described in the HEDIMED proposal D10.2 VTT ORDP: Open Research Data Pilot Jun 2020
Quality control procedures Procedures for quality control of laboratory analyses and data integrity D1.4 TAU Demonstrator Oct 2020
Dissemination and Exploitation plan Plan for dissemination and exploitation of the results and innovations generated by HEDIMED D11.3 TAU Report Dec 2020
Harmonization of existing data in clinical cohorts Generation of data matrix including data from clinical cohorts. D2.2 TAU Demonstrator Dec 2020

January 29, 2020